CMBI believes that 2025 is a crucial year for Kelun-Biotech as it transitions into a commercial biopharmaceutical company, with four product approvals expected and significant sales revenue projected. Despite an anticipated net loss due to commercialization efforts, the company's strong financial position and successful clinical trial results support a positive outlook. The target price has been raised, and a 'Buy' rating is maintained.
